CSL will pay $355 million upfront to co-develop Alentis Therapeutics’ anti-fibrosis candidate for kidney and liver indications, with potential future payments up to $1.2 billion. The deal structure signals continued big-pharma investment in fibrosis programs and expansion beyond single-compartment liver disease. The collaboration also emphasizes co-development as the preferred mechanism for absorbing late-stage fibrosis risk while sharing clinical and regulatory execution. For Alentis, the financing reduces runway pressure and accelerates development planning; for the sector, it reinforces that fibrosis remains a high-priority, partnership-ready therapeutic area.